Preliminary Final Report

Key points

• Revenues from ordinary activities down 36.39% to $46,280,283
• Loss from ordinary activities after tax up 179.10% to $(5,323,589)
• Net assets decreased from $28,085,315 to $24,494,461
• Final dividend paid on 23 December 2025 at 2.00 cents per security
• Audited financial statements with an unmodified opinion

Full summary

EZZ Life Science Holdings Ltd released its preliminary final report for the year ended 30 June 2026, showing a substantial decline in financial performance. Revenues from ordinary activities decreased by 36.39% to $46,280,283, while the loss from ordinary activities after tax rose by 179.10% to $(5,323,589). The company also reported a loss for the year attributable to the owners of $5,323,589, compared to a profit of $6,730,441 in the previous year. The net assets decreased from $28,085,315 as at 30 June 2025 to $24,494,461 as at 30 June 2026. Despite these challenges, the company maintained its final dividend at 2.00 cents per security, paid on 23 December 2025. The financial statements were audited and received an unmodified opinion.